Watch PROF. Know when insiders buy.
One email the day a filing lands. Free.
PROF
Profound Medical Corp.
5.80
−0.12 −2.03%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
84
PASS · shorts 84
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $211.9MP/E 12.6DIV YIELD —FCF YIELD —REV TTM $19.1M +61.2%NET INCOME −$32.7MNET CASH $33.8M52W 5.06 – 8.65SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.5M | +12.3% | 78.4% | −$11.1M | −$9.5M | — | -0.26 | −$11.3M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $5.3M | +103.6% | 71.8% | −$8M | −$7.1M | — | 0.19 | −$8.6M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $6M | +43.1% | 66.8% | −$7.4M | −$8.2M | — | 0.27 | −$6.6M | — | — | Mar 5 |
| Q3 2025 · Sep 30 | $5.3M | +86.8% | 74.3% | −$8.9M | −$8M | — | 0.26 | −$9.6M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $2.2M | −1.0% | 73.2% | −$13.8M | −$15.7M | — | -0.52 | −$13.7M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $2.6M | +82.1% | 70.7% | −$11.2M | −$10.7M | — | 0.36 | −$8.3M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $4.2M | — | 70.9% | −$8.3M | −$4.9M | — | 0.18 | −$5.9M | — | — | Mar 5 |
| Q3 2024 · Sep 30 | $2.8M | — | 63.1% | −$9M | −$9.4M | — | 0.38 | −$6.8M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $2.2M | — | 63.6% | −$7.8M | −$6.9M | — | 0.28 | −$6.2M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | $1.4M | — | 60.2% | −$7.9M | −$6.6M | — | 0.27 | −$4.5M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $16.1M | 70.8% | −$41.3M | −$42.6M | -264.4% | 1.41 | −$38.2M | $176K | −$38.4M | — | — |
| FY2024 · to Dec 31 | $10.7M | 65.9% | −$33.1M | −$27.8M | -260.4% | 1.12 | −$23.5M | — | — | — | — |
| FY2023 · to Dec 31 | $7.2M | 59.9% | −$28.7M | −$28.3M | -393.4% | 1.34 | −$22.6M | — | — | — | — |
Every number comes from Profound Medical Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.